Featuring perspectives from Dr Eileen M O&#x27;Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O&#x27;Reilly (28:05) CME information and select publications

Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

[SPEAKER_A] So we're going to talk about pancreatic cancer now. And you know, when we set up the agenda here, I was like, well, pancreatic cancer is number 2 here. Hopefully there's going to be enough to talk about. I wasn't so sure when we started planning here, but as we got into it, it looked more and more interesting. I was mentioning the fact that I was asking ChatGPT what was the most important advance in the past year in various tumors, Eileen, and One of the first answers they gave out was pan-RAS inhibition with daroxanabmine. Maybe I'll call it daroxanaroxamine. Is there a nickname for it yet?

[SPEAKER_B] Daroxanabmine.

[SPEAKER_A] Daroxanabmine. All right. Well, I'll do the best I can. Anyhow, Eileen O'Reilly and Philip A Philip join us here and Vic Malhotra from FCS. We're going to talk about pancreatic cancer. Here today. And before we get into it, I know Eileen's of course from Memorial Sloan Kettering. Philip is from the Henry Ford Cancer Center. And Vic is in Spring Hill, Florida as part of the FCS. So Vic, anything you want to ask the faculty? One thing I'm curious about is these new pan-RAS inhibitors. We're going to talk about that. Just kind of curious, start with you, Philip. Any thoughts about why pancreatic cancer seems to have so much resistance to systemic therapy over the years? And with the new development in terms of RAS inhibition, are we gonna see a new era here?

[SPEAKER_C] Yes, we will, for sure. Because pancreatic cancer, as you know, most of the people have, or most of the tumors contain the RAS mutation. And RAS mutation is central in the biology of the disease. For a long time we were not able to target RAS.

Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.